Therapeutic preferences of upadacitinib for patients with inflammatory bowel diseases: a nationwide study among Chinese physicians.

ABSTRACT:

Background

Upadacitinib (UPA) is a new small-molecule drug for treating inflammatory bowel disease (IBD); however, its therapeutic use in China remains limited.

Objectives

This study aimed to explore Chinese physicians' treatment preferences for UPA in IBD and analyze experience-related decision-making differences.

Design

A nationwide cross-sectional study conducted among Chinese physicians.

Methods

The study was conducted among Chinese physicians using a 69-item questionnaire on physicians' backgrounds and UPA preferences, covering (1) Physician backgrounds (12 items), (2) Therapeutic preferences regarding physicians' attention to different characteristics of UPA and physicians (24 items), and (3) clinical application practices (33 items). Physicians were cate

SUBMITTER: Yao L 

PROVIDER: S-EPMC12553892 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature